​

Astria Therapeutics (ATXS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ATXS Stock Forecast

Astria Therapeutics (ATXS) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $22.50, with a high of $25.00 and a low of $20.00. This represents a 456.93% increase from the last price of $4.04.

- $5 $10 $15 $20 $25 High: $25 Avg: $22.5 Low: $20 Last Closed Price: $4.04

ATXS Stock Rating

Astria Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

ATXS Price Target Upside V Benchmarks

TypeNameUpside
StockAstria Therapeutics456.93%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$25.00
Last Closing Price$4.04$4.04$4.04
Upside/Downside--518.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2526---8
Mar, 2526---8
Feb, 2526---8
Jan, 2516---7
Dec, 2416---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 21, 2024Hartaj SinghOppenheimer$25.00$9.59160.69%518.81%
Mar 26, 2024Hartaj SinghOppenheimer$29.00$14.12105.38%617.82%
Dec 19, 2022H.C. Wainwright$20.00$11.8169.35%395.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2025WedbushOutperformOutperformhold
Sep 25, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024OppenheimerOutperformOutperformhold
Jul 29, 2024Cowen & Co.Buyinitialise
May 21, 2024OppenheimerOutperformOutperformhold
Mar 26, 2024OppenheimerOutperformOutperformhold
Dec 19, 2022Piper SandlerBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.42$-1.68----
Avg Forecast$-2.24$-1.70$-1.78$-1.80$-2.04$-1.68
High Forecast$-1.94$-1.50$-1.61$-1.64$-1.76$-1.68
Low Forecast$-2.53$-1.79$-1.95$-2.09$-2.29$-1.68
Surprise %8.04%-1.18%----

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$1.25M$36.65M$90.10M
High Forecast---$1.25M$36.65M$90.10M
Low Forecast---$1.25M$36.65M$90.10M
Surprise %------

Net Income Forecast

$-95M $-85M $-75M $-65M $-55M $-45M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.89M$-94.26M----
Avg Forecast$-72.89M$-49.55M$-53.67M$-56.18M$-60.90M$-50.51M
High Forecast$-58.55M$-45.21M$-48.54M$-49.40M$-52.93M$-50.51M
Low Forecast$-76.14M$-53.88M$-58.80M$-62.96M$-68.88M$-50.51M
Surprise %-90.24%----

ATXS Forecast FAQ

Is Astria Therapeutics stock a buy?

Astria Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Astria Therapeutics is a favorable investment for most analysts.

What is Astria Therapeutics's price target?

Astria Therapeutics's price target, set by 6 Wall Street analysts, averages $22.5 over the next 12 months. The price target range spans from $20 at the low end to $25 at the high end, suggesting a potential 456.93% change from the previous closing price of $4.04.

How does Astria Therapeutics stock forecast compare to its benchmarks?

Astria Therapeutics's stock forecast shows a 456.93% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Astria Therapeutics over the past three months?

  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Astria Therapeutics’s EPS forecast?

Astria Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.78, marking a 5.95% increase from the reported $-1.68 in 2024. Estimates for the following years are $-1.8 in 2026, $-2.04 in 2027, and $-1.68 in 2028.

What is Astria Therapeutics’s revenue forecast?

Astria Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $1.25M, followed by $36.65M for 2027, and $90.1M for 2028.

What is Astria Therapeutics’s net income forecast?

Astria Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-53.671M, representing a -43.06% decrease from the reported $-94.26M in 2024. Projections indicate $-56.18M in 2026, $-60.905M in 2027, and $-50.507M in 2028.